Innovative Therapies Centers of Excellence Act of 2025
Summary
HR2623 mandates the VA to establish five innovative therapies centers focused on advanced treatments including psychedelics. The bill is in early committee stage with 27 cosponsors and no appropriated funding yet. The tickers CMPS, GHRS, ATAI, and DRUG have rallied significantly over 30 days (17% to 52%) on the Executive Order and legislative signal, but remain well below 52-week highs.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2623 is a policy authorization with zero allocated funding — the market is pricing in future appropriations that do not yet exist.
- 2.All four psychedelic tickers have rallied 17-52% in 30 days but have 7-day declines of 0.2-12.4%, indicating profit-taking after the Executive Order pop.
- 3.The VA is the ideal first customer for psychedelic therapies due to the high veteran PTSD/depression prevalence, but commercialization is 2-4 years away.
- 4.Companion bill S4031 increases passage probability, but the authorization-appropriation gap remains the critical risk factor.
Market Implications
The four pure-play psychedelic developers (CMPS $8.39, GHRS $19.27, ATAI $4.17, DRUG $88.97) have already priced in significant legislative optimism with 30-day gains of 17-52%. The 7-day pullback (CMPS -12.4%, ATAI -9.9%) suggests the market is repricing the probability and timeline of actual appropriations. These stocks remain highly speculative — they are all below their 52-week highs (CMPS: 82% of high, GHRS: 78%, ATAI: 62%, DRUG: 72%) and face binary risk from the appropriations process. Investors should monitor the House VA Committee markup schedule and any FY2027 VA appropriations language. The structural bull case is intact — the VA is the ideal early adopter — but near-term momentum has stalled as the legislative reality (zero funding, early stage) sets in.
Full Analysis
HR2623, the 'Innovative Therapies Centers of Excellence Act of 2025,' was introduced in the House on April 3, 2025, by Rep. Correa (D-CA) and referred to the House Veterans' Affairs Committee. The bill requires the VA to designate at least five medical facilities as innovative therapies centers to research and deliver advanced treatments, explicitly including psychedelic-based therapies for conditions like PTSD and depression. A companion bill (S4031) has been introduced in the Senate, and an Executive Order has separately directed acceleration of psychedelic treatment reviews.
Crucially, the bill authorizes the establishment of these centers but explicitly states operations are 'subject to the availability of appropriations.' This is an authorization bill — it sets policy direction and creates a legal framework, but allocates zero dollars. Actual funding requires a separate appropriations bill. The bill has 27 cosponsors (bipartisan: Correa, Bergman, Crenshaw, Khanna, Luttrell) but remains in early committee stage with only four actions to date.
The psychedelic therapy sector has four publicly traded pure-plays: CMPS ($8.39), GHRS ($19.27), ATAI ($4.17), and DRUG ($88.97). All four have rallied sharply over the past 30 days (CMPS +51.7%, GHRS +37%, ATAI +17.8%, DRUG +21.9%) following the Executive Order announcement. However, the 7-day trend is negative (CMPS -12.4%, GHRS -4.9%, ATAI -9.9%, DRUG -0.2%), suggesting the initial Executive Order pop is fading as investors recognize the authorization-appropriation gap.
The structural winners remain the pure-play psychedelic developers because the VA represents the single largest concentrated patient population for PTSD/depression (over 1 million veterans diagnosed). Unlike the commercial insurance path (requiring lengthy reimbursement approvals), a VA center of excellence can directly procure and administer therapies. However, the legislative timeline is lengthy: the bill must pass committee, pass the House, pass the Senate (companion S4031 helps), and then secure an appropriations rider. This is a multi-year catalyst, not an imminent revenue event.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Bill mandates the VA to designate at least five medical facilities as 'innovative therapies centers of excellence' to research and deliver advanced treatments, including psychedelic-based therapies, subject to future appropriations. An Executive Order accelerating psychedelic treatments provides policy tailwind.
Who must act
Secretary of Veterans Affairs, under the Under Secretary for Health, must designate facilities and establish centers upon appropriation.
What happens
Creates a federal procurement pathway for psychedelic drug development contracts and clinical trial services targeting PTSD and depression in the veteran population (the single largest eligible cohort for such treatments).
Stock impact
CMPS is the leading pure-play developer of psilocybin therapy (COMP360), currently in Phase 3 for treatment-resistant depression. VA adoption would open a direct government procurement channel for its therapy, drastically shortening commercial adoption timelines and reducing dependence on private insurance/reimbursement.
What the bill does
Same as above — bill mandates VA innovation centers that integrate psychedelic therapies; Executive Order accelerates regulatory pathway.
Who must act
Secretary of Veterans Affairs
What happens
Creates federal demand signal for mecamylamine-based therapies (GHRS's lead candidate, GH001) for treatment-resistant depression, with VA as a first-mover adopter rather than waiting for commercial insurance coverage.
Stock impact
GHRS is developing intranasal mecamylamine for psychiatric disorders. VA centers of excellence would provide a clinical deployment venue for its lead candidate, reducing time-to-revenue and providing federal reimbursement clarity.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Mental Health Research Accelerator Act of 2025
Freedom to Heal Act of 2025
Freedom to Heal Act of 2025
Veterans Health Administration Novel Therapeutics Preparedness Act
SUPPORT for Patients and Communities Reauthorization Act of 2025
MERCK SHARP & DOHME LLC: $2.4B Department of Health and Human Services Contract Vehicle
BOLLINGER SHIPYARDS LOCKPORT, L.L.C.: $2.1B Department of Homeland Security Contract
DAVIE DEFENSE INC.: $3.5B Department of Homeland Security Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Presidential Determination Pursuant to Section 101 of the Defense Production Act of 1950, as Amended, on Recoverable Critical Minerals and Materials
This memorandum invokes the Defense Production Act (DPA) Section 101 to declare that recoverable critical minerals and materials (such as black mass, end-of-life rare-earth magnets, and scrap) are essential to national defense and that the U.S. cannot meet defense needs without disrupting civilian markets. It directs the Secretary of Commerce to issue regulations and take actions—including priority contracts and supply-chain interventions—to rapidly expand domestic recovery and processing of these materials, while explicitly excluding copper scrap already covered by a separate proclamation.
Further Strengthening Actions Taken to Adjust Imports of Aluminum into the United States
This proclamation modifies the Section 232 tariff regime on aluminum imports by authorizing the Secretary of Commerce to establish a program that incentivizes new U.S. investment in primary aluminum production. Companies with approved onshoring plans can import primary aluminum at half the standard Section 232 duty rate, up to the anticipated annual output of their new or expanded facilities, with construction required to start by January 20, 2029. The action aims to boost domestic primary aluminum supply for national security and defense industrial base needs.
Securing America’s Defense Supply Chains and Ensuring Domestic Acquisition of Critical Materials
This executive order restricts waivers for foreign-sourced critical materials in defense contracts, effective January 1, 2027, and mandates that defense contractors map their supply chains from raw materials to end products, vet subcontractors for risks, and prohibit covered materials from unreliable foreign suppliers. It directs the Secretary of War to enforce strict compliance, including requiring mitigation plans for any non-compliant materials and establishing penalties for fraud or willful noncompliance.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →